simendan has been researched along with Disease Exacerbation in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Chalabi, A; Heunks, LMA; Papp, Z; Pollesello, P | 1 |
| Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S | 1 |
| Bacaksiz, A; Erdogan, E; Ergelen, M; Erturk, M; Karakurt, H; Sonmez, O; Tasal, A; Turfan, M; Uyarel, H; Vatankulu, MA | 1 |
| Freeman, LJ; Rafiq, I | 1 |
| Birant, A; Eksik, A; Erturk, M; Kalkan, AK; Karakurt, H; Mansiroglu, AK; Oner, E; Ozturk, D; Somuncu, MU | 1 |
| Feola, M; Ferreri, C; Leto, L; Testa, M | 1 |
| Belenkov, Y; Cleland, JG; Eha, J; Kivikko, M; Nieminen, MS; Põder, P; Sarapohja, T | 1 |
| Marino, P; Meryon, IC | 1 |
| Chalikias, GK; Hatseras, DI; Hatzinikolaou, HI; Kaski, JC; Kortsaris, AX; Maltezos, E; Papanas, N; Stakos, DA; Tentes, IK; Tziakas, DN | 1 |
| González-Chon, O; Guevara, M; Márquez, MF; Rivera, J; Romero, KA; Uruchurtu, E | 1 |
2 review(s) available for simendan and Disease Exacerbation
| Article | Year |
|---|---|
Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis: An Overview of a Working Hypothesis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Diaphragm; Disease Progression; Humans; Motor Neurons; Muscle Strength; Neuromuscular Agents; Recovery of Function; Respiration; Respiratory Insufficiency; Simendan; Treatment Outcome | 2019 |
Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Topics: Aged; Disease Progression; Dobutamine; Dopamine; Epinephrine; Female; Hemodynamics; Humans; Male; Middle Aged; Milrinone; Natriuretic Peptide, Brain; Network Meta-Analysis; Norepinephrine; Patient Safety; Recombinant Proteins; Shock, Cardiogenic; Simendan; Treatment Outcome | 2020 |
2 trial(s) available for simendan and Disease Exacerbation
| Article | Year |
|---|---|
Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Topics: Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Psychometrics; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Surveys and Questionnaires | 2008 |
Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure.
Topics: Aged; Cardiotonic Agents; Disease Progression; Female; Heart Failure; Humans; Hydrazones; Injections, Intravenous; Male; Matrix Metalloproteinase 2; Placebos; Pyridazines; Simendan; Treatment Outcome | 2005 |
6 other study(ies) available for simendan and Disease Exacerbation
| Article | Year |
|---|---|
Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Disease Progression; Dobutamine; Female; Heart Failure; Hospital Mortality; Humans; Hydrazones; Infusions, Intravenous; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Pyridazines; Retrospective Studies; Simendan | 2014 |
Pulsed levosimendan therapy in the management of chronic end stage cardiac failure in 'adult congenital heart disease'.
Topics: Adult; Cardiac Surgical Procedures; Cardiotonic Agents; Disease Progression; Female; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Life Expectancy; Male; Middle Aged; Postoperative Complications; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Treatment Outcome | 2015 |
Assessment of sustained effects of levosimendan on right ventricular systolic functions in patients with advanced heart failure.
Topics: Aged; Biological Availability; Cardiotonic Agents; Disease Progression; Echocardiography, Doppler; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Treatment Outcome; Ventricular Function, Right | 2016 |
The worsening renal failure in a chronic cardio-renal syndrome type II: efficacy of a single levosimendan infusion.
Topics: Aged; Cardio-Renal Syndrome; Disease Progression; Humans; Hydrazones; Infusions, Intravenous; Male; Pyridazines; Renal Insufficiency; Simendan; Treatment Outcome; Vasodilator Agents | 2016 |
Novel strategies for the management of right ventricular failure with pulmonary hypertension.
Topics: Adult; Anti-Bacterial Agents; Antihypertensive Agents; Ascites; Cardiotonic Agents; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Echocardiography; Electrocardiography; Epoprostenol; Female; Humans; Hydrazones; Hypertension, Pulmonary; Paracentesis; Pyridazines; Simendan; Ventricular Dysfunction, Right | 2012 |
Severe stunned myocardium after lightning strike.
Topics: Adult; Cardiotonic Agents; Causality; Critical Care; Disease Progression; Echocardiography; Electrocardiography; Epilepsy, Tonic-Clonic; Exercise Test; Female; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Lightning Injuries; Monitoring, Physiologic; Myocardial Stunning; Pyridazines; Radiopharmaceuticals; Recovery of Function; Severity of Illness Index; Shock, Cardiogenic; Simendan; Technetium Tc 99m Sestamibi; Thallium; Ventricular Dysfunction, Left | 2007 |